MCMaria-Ioanna Christodoulou

Maria-Ioanna Christodoulou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria-Ioanna Christodoulou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Eirini Maratou

    Second Department of Internal Medicine, School of Medicine, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece

    3 shared publications
  • Eleni Boutati

    Second Department of Internal Medicine, School of Medicine, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece

    3 shared publications
  • Emmanuel G. Fragoulis

    Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece

    3 shared publications
  • Panayota Mitrou

    Ministry of Health, Athens, Greece

    3 shared publications
  • Andreas Scorilas

    Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece

    2 shared publications
  • Christos K. Kontos

    Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Athens, Greece

    2 shared publications

Latest Publications

  • Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome

    by Margaritis Avgeris, Ioanna Kokkinopoulou, Eirini Maratou, Panayota Mitrou, Eleni Boutati, Andreas Scorilas, Emmanuel G. Fragoulis, Maria-Ioanna Christodoulou


  • Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals

    by Ioanna Kokkinopoulou, Eirini Maratou, Panayota Mitrou, Eleni Boutati, Diamantis C. Sideris, Emmanuel G. Fragoulis, Maria-Ioanna Christodoulou

    Certain microRNA molecules (miRNAs) that target genes involved in beta-cell growth and insulin resistance are found deregulated in patients with type-2 diabetes mellitus (T2D) and correlate with its complications. However, the expression profile of miRNAs that regulate genes bearing T2D-related single-nucleotide polymorphisms has been hardly studied. We recently reported that the mRNA patterns of specific T2D-susceptibility genes are impaired in patients, and associate with disease parameters and risk factors. The aim of this study was to explore the levels of miRNAs that target those genes, in peripheral blood of patients versus controls.


  • Open Access

    Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk

    by Maria-Ioanna Christodoulou, Margaritis Avgeris, Ioanna Kokkinopoulou, Eirini Maratou, Panayota Mitrou, Christos K. Kontos, Efthimios Pappas, Eleni Boutati, Andreas Scorilas, Emmanuel G. Fragoulis

    Despite significant progress by genome-wide association studies, the ability of genetic variants to conduce to the prediction or prognosis of type-2 diabetes (T2D) is weak. Expression analysis of the corresponding genes may suggest possible links between single-nucleotide polymorphisms and T2D phenotype and/or risk. Herein, we investigated the expression patterns of 24 T2D-susceptibility genes, and their individual transcript variants (tv), in peripheral blood of T2D patients and controls (CTs), applying RNA-seq and real-time qPCR methodologies, and explore possible associations with disease features. Our data revealed the deregulation of certain transcripts in T2D patients. Among them, the down-regulation of CAPN10 tv3 was confirmed as an independent predictor for T2D. In patients, increased expression of CDK5 tv2, CDKN2A tv3 or THADA tv5 correlated positively with serum insulin levels, of CDK5 tv1 positively with % HbA1c levels, while in controls, elevated levels of TSPAN8 were associated positively with the presence of T2D family history. Herein, a T2D-specific expression profile of specific transcripts of disease-susceptibility genes is for the first time described in human peripheral blood. Large-scale studies are needed to evaluate the potential of these molecules to serve as disease biomarkers.


  • Nature Promises New Anticancer Agents: Interplay with the Apoptosis-related BCL2 Gene Family

    by Maria-Ioanna Christodoulou, Christos K. Kontos, Maria Halabalaki, Alexios-Leandros Skaltsounis, Andreas Scorilas

    Natural products display special attributes in the treatment and prevention of a variety of human disorders including cancer. Their therapeutic capacities along with the fact that nature comprises a priceless pool of new compounds have attracted the interest of researchers worldwide. A significant number of organic compounds from terrestrial and marine organisms exhibit anticancer properties as attested by both in vitro and in vivo studies. Emerging evidence supporting the antineoplastic activity of natural compounds has rendered them promising agents in the fight against cancer. As a result, numerous natural compounds or their derivatives have entered clinical practice and are currently in the forefront of chemotherapeutics, showing beneficial effects for cancer patients. Induction of apoptosis seems to be the major mechanism of action induced by these natural agents in the race against cancer. This is mainly achieved through modulations of the expression of B-cell CLL/lymphoma 2 (BCL2) family members. These molecules appear to be the pivotal players determining cellular fate. In the current review, we provide a comprehensive overview of the major alterations in the gene and/or protein levels of BCL2-family members evoked in cancer cells after treatment with a gamut of natural compounds. The data cited suggest the need for exploitation of newly discovered natural products that, along with the improvement of currently employed chemotherapeutics, will significantly enrich the anticancer armamentarium.